Loading stock data…
ACHC
$25.01-0.17 (-0.68%)
Pre-Market$25.04+0.02 (+0.10%)· Last close May 11
Acadia Healthcare Company, Inc.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Acadia Healthcare Company, Inc. in the Healthcare sector is trading at $25.01. The stock is currently 17% below its 52-week high of $30.20, remaining 22.4% above its 200-day moving average. Technical signals show neutral RSI of 40 and bearish MACD signal, explaining why ACHC maintains its current momentum and trend strength. The Whystock Score of 75/100 reflects a high-conviction bullish alignment.
Ecosystem Influences
Neutral momentum (RSI 40) — price action in range
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$25.01
Potential Upside
5%
Whystock Fair Value$26.26
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus14 analysts
Buy
Mean target$28.46+13.8%
Range$13.00 – $39.00
Fundamentals
Acadia Healthcare Company, Inc. provides behavioral healthcare services in the United States and Puerto Rico. The company owns and operates acute inpatient psychiatric facilities; specialty treatment facilities comprising residential recovery facilit...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$2.58B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.71
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
7.14%
Volume
Today's trading volume
1.51M
Recent News
RBC Capital Lifts PT on Acadia Healthcare Company (ACHC) Following Q1 Earnings Beat
Acadia Healthcare Company, Inc. (NASDAQ:ACHC) is one of the best performing healthcare stocks so far in 2026. Acadia Healthcare Company, Inc. (NASDAQ:ACHC) received a rating update from RBC Capital on May 4, with the firm lifting the price target on the stock to $31 from $28 and reiterating an Outperform rating on the shares. The […]
Acadia Healthcare Company (ACHC) Is Down 5.5% After Q1 Revenue Rises But Earnings Decline - What's Changed
In late April 2026, Acadia Healthcare Company reported first-quarter 2026 results showing sales of US$828.8 million, higher than a year earlier, while net income and earnings per share from continuing operations both declined compared with the prior-year period. At the same time, the company issued second-quarter 2026 revenue guidance of US$835 million to US$850 million, highlighting management’s focus on top-line expansion even as profitability pressures persist. Next, we’ll examine how...
Acadia Healthcare Q1 Earnings Beat Estimates on Rising Patient Days
ACHC Q1 tops estimates with 37 cents EPS and 7.6% revenue growth, driven by higher patient days and admissions despite shorter stays and rising costs.
AMD downgraded, Airbnb upgraded: Wall Street's top analyst calls
AMD downgraded, Airbnb upgraded: Wall Street's top analyst calls
ACHC Q1 Deep Dive: Operational Changes and Payer Headwinds Shape Outlook
Behavioral health company Acadia Healthcare (NASDAQ:ACHC) reported revenue ahead of Wall Street’s expectations in Q1 CY2026, with sales up 7.6% year on year to $828.8 million. On the other hand, next quarter’s revenue guidance of $842.5 million was less impressive, coming in 2.7% below analysts’ estimates. Its non-GAAP profit of $0.37 per share was 39.7% above analysts’ consensus estimates.